Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eddingpharm Gains China Rights for Cancer Drug from Syndax

publication date: Sep 4, 2013
Eddingpharm has in-licensed China rights to a clinical-stage cancer treatment from Syndax Pharma of Massachusetts. Entinostat is an oral epigenetic drug that was designed to reverse resistance to targeted oncology therapies. Eddingpharm will develop the drug in China, a process that includes participating in Syndax’s global Phase III trials of the drug. It will also have manufacturing rights to entinostat. Syndax will receive milestone and royalty payments from Eddingpharm for entinostat, though specific amounts were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital